16 Jul 2025
30m
Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.